Merit Medical reported Q4 FY2025 revenue of USD 393.9 million (+11.0%), with GAAP operating margin of 13.8% and GAAP EPS of USD 0.63 (+37.0%). Q4 GAAP net income was USD 38.0 million, while free cash flow was USD 74.0 million (+13.0%). Non-GAAP EPS was USD 1.04 (+12.0%) and non-GAAP operating margin was 21.0%. For FY2025, Merit Medical posted revenue of USD 1.516 billion (+12.0%), GAAP operating margin of 12.2%, GAAP EPS of USD 2.13 (+5.0%) and GAAP net income of USD 128.5 million. FY2025 free cash flow totaled USD 215.7 million (+16.0%), and non-GAAP EPS was USD 3.83 (+11.0%). The company ended FY2025 with cash and cash equivalents of USD 446.4 million and total debt obligations of USD 747.5 million. In corporate updates, Merit Medical said it reorganized its sales teams and product categories effective January 1, 2025 to include spine device revenues under its OEM product category, with FY2024 revenue recast for comparability. Management also highlighted progress on its Continued Growth Initiatives Program, which runs through December 31, 2026. For FY2026, Merit Medical guided for total revenue of USD 1.610 billion to USD 1.630 billion (+6.0% to +8.0%) and non-GAAP EPS of USD 4.01 to USD 4.15 (+5.0% to +8.0%).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merit Medical Systems Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602241605PRIMZONEFULLFEED9660544) on February 24, 2026, and is solely responsible for the information contained therein.